Nagao Mizuho, Ikeda Masanori, Fukuda Norimasa, Habukawa Chizu, Kitamura Tetsuro, Katsunuma Toshio, Fujisawa Takao
Allergy Center, Mie National Hospital, Tsu, Japan.
Department of Pediatrics, Fukuyama Medical Center, Fukuyama, Japan.
Allergol Int. 2018 Jan;67(1):72-78. doi: 10.1016/j.alit.2017.04.008. Epub 2017 May 16.
While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed β-agonists in this population, we conducted a randomized controlled trial.
Eligible patients were children aged 1-5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed β-agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219.
From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively (P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92; P = 0.033).
Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week.
日本指南建议对每月出现一次以上哮喘症状的学龄前儿童进行初始控制治疗,而西方指南则不然。为了确定孟鲁司特控制治疗在该人群中是否比按需使用β-激动剂更有效,我们进行了一项随机对照试验。
符合条件的患者为1至5岁、每月出现一次以上但每周少于一次哮喘症状的儿童。患者按1:1比例随机分配,接受每日4毫克孟鲁司特治疗48周或按需使用β-激动剂。主要终点是开始吸入糖皮质激素强化治疗前急性哮喘加重的次数。本研究已在大学医院医学信息网络临床试验注册中心注册,注册号为UMIN000002219。
从2009年9月至2012年11月,93名患者(孟鲁司特组47名,无控制组46名)纳入研究。所有患者均纳入分析。研究期间,孟鲁司特组13名患者(28%)、无控制组23名患者(50%)出现急性加重,年平均次数分别为0.9次和1.9次(P = 0.027)。此外,分别有10名(21%)和19名(41%)患者接受了强化治疗。孟鲁司特组强化治疗的累积发生率显著较低(风险比0.45,95%置信区间0.21至0.92;P = 0.033)。
孟鲁司特是一种有效的控制治疗方法,适用于每月出现一次以上但每周少于一次哮喘症状的学龄前儿童。